Researchers say, under the right conditions, tests of lung fluid can be as effective as tissue biopsy for diagnosing mesothelioma.

Raleigh, NC (PRWEB) October 13, 2015

Scientists in Seattle and Vancouver compared the diagnostic value of lung fluid cytology (effusion cytology) versus tissue biopsy in 18 patients with or without mesothelioma. Surviving Mesothelioma has just posted an article on the new research. Click here to read it now.

The doctors from PhenoPath Laboratories in Seattle and the University of British Columbia found that certain genetic alterations were seen just as often in the fluid samples of mesothelioma patients as they were in tissue samples.

“We conclude that both BAP1 immunohistochemistry and p16 FISH analysis provide reliable markers of mesothelial malignancy [mesothelioma] in effusion cytology specimens,” writes lead researcher Harry Hwang, MD, of PhenoPath Laboratories in Seattle.

The study, published in the American Journal of Surgical Pathology, found that none of the people with benign disease had changes in BAP1 or p16 in either their tissue or their lung fluid.

“While the idea of diagnosing mesothelioma from lung fluid samples remains controversial, if these results can be replicated in future studies, it could potentially improve mesothelioma outcomes by making diagnosis simpler and faster,” says Surviving Mesothelioma Managing Editor Alex Strauss.

Find out how effusion cytology stacks up against tissue biopsy for mesothelioma diagnosis in Lung Fluid Versus Tissue Biopsy for Mesothelioma Diagnosis, now available on the Surviving Mesothelioma website.

Hwang, HC, et al, “Utility of BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens”, October 6, 2015, American Journal of Surgical Pathology, Epub ahead of print,

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

advertisement | advertise on newsday

For the original version on PRWeb visit: